Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAKIN trial of subcutaneous anakinra in cystic fibrosis
2023-510376-31-00Phase 2Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Jan 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anakinra in cystic fibrosis (CF) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Absolute pre-post change in lung clearance index. Started Jan 2024; status: completed.
02
Drugs
anakinra
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2023-510376-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510376-31-00.